RAZ0RPRISM
All collisions
Frontier Brief · Collision 2026

Function (biology)×Virology

42.8Collision Index
2.9%historical odds of first co-publication

This pair ranks in the top 0.1% of every collision candidate in the corpus. Across held-out years, pairs scoring that well went on to co-publish at 10.0× the base rate, typically within 2 years.

How this was measured →
Frontier Brief

The Frontier Brief for this collision is still being written. The evidence below already reflects the current model run.

Players in this space · predicted

Pre-company space. No named players have staked this collision yet — an emerging pairing where the field, not a firm, is the story so far.

Who actually spans both fields · graph-verified

18 researchers publish on both sides of this collision without the fields themselves having met. Every name below is counted from papers in the corpus — not inferred.

ResearcherFunction / Virology
  • Hans CleversLustgarten Foundation
    13
  • Peter J. PetersRadboud Institute for Molecular Life Sciences
    12
  • George F. GaoShenzhen Second People's Hospital
    12
  • Lei S. QiMammoth Biosciences (United States)
    21
  • Rik G.H. LindeboomRadboud University Medical Center
    11
  • Inha HeoShandong University
    11
  • Benedetta ArtegianiRadboud University Nijmegen
    11
  • Josef PenningerUniversité Grenoble Alpes
    11
  • Astrid HagelkrüysMedical University of Vienna
    11
  • Li LiNovartis (Switzerland)
    11
Institutionpapers each side
  • Harvard UniversityUS
    3362
  • University College LondonGB
    2640
  • Stanford UniversityUS
    3226
  • National Institutes of HealthUS
    1163
  • Howard Hughes Medical InstituteUS
    2330
  • University of CambridgeGB
    2128
Closest work to the seambridge fields touched

Counted from the corpus. Institution counts use best-effort affiliation (every author on a paper is paired with every institution on it), so read them as presence, not headcount.

Deep-Dive

A premium Deep-Dive is being generated for this collision — check back soon.